Covered recipient · General Payments record
NAVID EZRA
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$160,808.97
169 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $148,733.50 | 55 |
| Travel and Lodging | $7,257.02 | 41 |
| Food and Beverage | $4,768.45 | 72 |
| Education | $50.00 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $76,275.67 | 56 |
| ABBVIE INC. | $60,783.63 | 69 |
| Amgen Inc. | $11,356.62 | 20 |
| UCB, Inc. | $6,367.74 | 5 |
| E.R. Squibb & Sons, L.L.C. | $5,482.97 | 5 |
| Novartis Pharmaceuticals Corporation | $164.55 | 2 |
| GENZYME CORPORATION | $126.04 | 4 |
| Dermavant Sciences, Inc. | $105.28 | 1 |
| PFIZER INC. | $44.36 | 2 |
| Organogenesis Inc. | $38.95 | 2 |
| LEO Pharma Inc. | $22.36 | 1 |
| Sun Pharmaceutical Industries Inc. | $21.76 | 1 |
| Galderma Laboratories, L.P. | $19.04 | 1 |
Page 3 of 4; records 101–150 of 169 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
NAVID EZRA
NPI 1104110071 · CMS profile ID 230966
Allopathic & Osteopathic Physicians / Dermatology
THOUSAND OAKS, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 169 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1104110071?year=2023&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- NAVID EZRA, NPI 1104110071, CMS profile ID 230966. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 169 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104110071?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). NAVID EZRA, NPI 1104110071, CMS profile ID 230966. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 169 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104110071?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- NAVID EZRA, NPI 1104110071, CMS profile ID 230966, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 169 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1104110071?year=2023&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
169 matching records · $160,808.97 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 169.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | $24.74 | 03/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020647783 | CMS |
| ABBVIE INC. | $1,725.00 | 03/16/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997223503 | CMS |
| Lilly USA, LLC | $21.80 | 03/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031924393 | CMS |
| Lilly USA, LLC | $125.00 | 03/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032068039 | CMS |
| Lilly USA, LLC | $8.36 | 03/15/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032068043 | CMS |
| ABBVIE INC. | $6.31 | 03/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997223499 | CMS |
| ABBVIE INC. | $2,875.00 | 03/13/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997223501 | CMS |
| ABBVIE INC. | $8.00 | 03/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997223497 | CMS |
| ABBVIE INC. | $121.12 | 03/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997223495 | CMS |
| ABBVIE INC. | $2,875.00 | 03/06/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997223493 | CMS |
| Lilly USA, LLC | $1,800.00 | 03/06/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032091439 | CMS |
| Organogenesis Inc. | $24.54 | 03/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048111413 | CMS |
| ABBVIE INC. | $28.45 | 03/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997223491 | CMS |
| Galderma Laboratories, L.P. | $19.04 | 03/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059693871 | CMS |
| ABBVIE INC. | $124.99 | 03/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997223489 | CMS |
| Lilly USA, LLC | $1,350.00 | 02/27/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031924389 | CMS |
| Lilly USA, LLC | $3,600.00 | 02/27/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032068021 | CMS |
| Novartis Pharmaceuticals Corporation | $102.00 | 02/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991592553 | CMS |
| GENZYME CORPORATION | $24.52 | 02/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050270743 | CMS |
| PFIZER INC. | $20.65 | 02/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049627783 | CMS |
| Lilly USA, LLC | $3,150.00 | 02/22/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031924379 | CMS |
| Lilly USA, LLC | $3,600.00 | 02/22/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032091443 | CMS |
| Lilly USA, LLC | $2,250.00 | 02/22/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032091445 | CMS |
| ABBVIE INC. | $20.56 | 02/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997223485 | CMS |
| ABBVIE INC. | $27.23 | 02/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997223487 | CMS |
| Lilly USA, LLC | $3,600.00 | 02/21/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031924383 | CMS |
| Lilly USA, LLC | $121.82 | 02/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031965173 | CMS |
| Lilly USA, LLC | $16.09 | 02/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032091449 | CMS |
| Amgen Inc. | $30.96 | 02/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020647781 | CMS |
| Amgen Inc. | $27.29 | 02/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020647779 | CMS |
| ABBVIE INC. | $2,875.00 | 02/15/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997223483 | CMS |
| Lilly USA, LLC | $6,750.00 | 02/15/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031965159 | CMS |
| Lilly USA, LLC | $3,600.00 | 02/15/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032040575 | CMS |
| Lilly USA, LLC | $2,250.00 | 02/15/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032114613 | CMS |
| GENZYME CORPORATION | $26.57 | 02/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050270733 | CMS |
| ABBVIE INC. | $125.00 | 02/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997223481 | CMS |
| Lilly USA, LLC | $32.46 | 02/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031965177 | CMS |
| Lilly USA, LLC | $17.76 | 02/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032114621 | CMS |
| Lilly USA, LLC | $329.00 | 02/01/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031955563 | CMS |
| Lilly USA, LLC | $271.80 | 02/01/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031955569 | CMS |
| Lilly USA, LLC | $49.89 | 02/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031965153 | CMS |
| Lilly USA, LLC | $252.65 | 02/01/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032040557 | CMS |
| Lilly USA, LLC | $160.80 | 02/01/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032067997 | CMS |
| Lilly USA, LLC | $139.66 | 02/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032068003 | CMS |
| Lilly USA, LLC | $3,600.00 | 02/01/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032068013 | CMS |
| Lilly USA, LLC | $2,250.00 | 02/01/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032068017 | CMS |
| Lilly USA, LLC | $50.00 | 02/01/2023 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032091423 | CMS |
| Lilly USA, LLC | $44.89 | 02/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032091427 | CMS |
| Lilly USA, LLC | $59.85 | 02/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032091431 | CMS |
| Lilly USA, LLC | $160.80 | 02/01/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032091435 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,176,536.15 | 478 |
| PY2024 | Recipient | $9,541.92 | 12 |
| PY2024 | Principal investigator | $2,209,399.58 | 227 |
| PY2023 | Recipient | $24,485.31 | 12 |
| PY2023 | Principal investigator | $601,126.30 | 163 |
| PY2022 | Principal investigator | $454,041.07 | 141 |
| PY2021 | Principal investigator | $632,449.47 | 86 |
| PY2020 | Principal investigator | $400,504.22 | 83 |
| PY2019 | Recipient | $3,000.00 | 1 |
| PY2019 | Principal investigator | $472,308.11 | 34 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
478 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $665.04 | 12/31/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 4 Multicenter, Randomized, Double-Blind Study of Risankizumab for the Treatment of Adult Subjects with Moderate to Severe Genital Psoriasis or Moderate to Severe Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202533893 |
| Principal investigator 1 | ABBVIE INC. | $1,529.40 | 12/31/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata | No dispute reported | 06/30/2026 | 1202533895 |
| Principal investigator 1 | ABBVIE INC. | $3,537.36 | 12/31/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy | No dispute reported | 06/30/2026 | 1202533897 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $14,000.00 | 12/26/2025 | Non-covered Recipient Entity Northridge Clinical Trials | A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) | No dispute reported | 06/30/2026 | 1235995273 |
| Principal investigator 1 | Incyte Corporation | $1,555.20 | 12/19/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240482147 |
| Principal investigator 1 | Incyte Corporation | $1,663.00 | 12/19/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561119 |
| Principal investigator 1 | Incyte Corporation | $1,670.00 | 12/19/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561146 |
| Principal investigator 1 | Incyte Corporation | $1,670.00 | 12/19/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561152 |
| Principal investigator 1 | Incyte Corporation | $52.00 | 12/19/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561221 |
| Principal investigator 1 | Incyte Corporation | $52.00 | 12/19/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561227 |
| Principal investigator 1 | Incyte Corporation | $52.00 | 12/19/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561233 |
| Principal investigator 1 | Incyte Corporation | $52.00 | 12/19/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561239 |
| Principal investigator 1 | Incyte Corporation | $52.00 | 12/19/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561244 |
| Principal investigator 1 | Incyte Corporation | $52.00 | 12/19/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561249 |
| Principal investigator 1 | Incyte Corporation | $52.00 | 12/19/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561254 |
| Principal investigator 1 | Incyte Corporation | $52.00 | 12/19/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561261 |
| Principal investigator 1 | Incyte Corporation | $52.00 | 12/19/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561268 |
| Principal investigator 1 | Incyte Corporation | $1,922.00 | 12/19/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561272 |
| Principal investigator 1 | Incyte Corporation | $1,922.00 | 12/19/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561278 |
| Principal investigator 1 | Incyte Corporation | $2,244.00 | 12/19/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561354 |
| Principal investigator 1 | Incyte Corporation | $1,968.00 | 12/19/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561431 |
| Principal investigator 1 | Incyte Corporation | $1,968.00 | 12/19/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561435 |
| Principal investigator 1 | Incyte Corporation | $2,047.00 | 12/19/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561441 |
| Principal investigator 1 | Incyte Corporation | $2,071.00 | 12/19/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561449 |
| Principal investigator 1 | Incyte Corporation | $2,168.00 | 12/19/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561455 |
| Principal investigator 1 | Incyte Corporation | $3,642.00 | 12/19/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561472 |
| Principal investigator 1 | Incyte Corporation | $2,335.00 | 12/19/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561476 |
| Principal investigator 1 | Incyte Corporation | $2,335.00 | 12/19/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561481 |
| Principal investigator 1 | Incyte Corporation | $198.00 | 12/18/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561395 |
| Principal investigator 1 | Incyte Corporation | $99.00 | 12/18/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561466 |
| Principal investigator 1 | Incyte Corporation | $11,050.00 | 12/17/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240519548 |
| Principal investigator 1 | Incyte Corporation | $2,077.00 | 12/17/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240519552 |
| Principal investigator 1 | Incyte Corporation | $99.00 | 12/17/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561315 |
| Principal investigator 1 | Incyte Corporation | $83.00 | 12/17/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561385 |
| Principal investigator 1 | Incyte Corporation | $635.00 | 12/17/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561538 |
| Principal investigator 1 | Incyte Corporation | $138.00 | 12/17/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561565 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $200.00 | 12/17/2025 | Non-covered Recipient Entity Northridge Clinical Trials Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226103316 |
| Principal investigator 1 | PFIZER INC. | $18,056.28 | 12/16/2025 | Non-covered Recipient Entity Northridge Clinical Trials | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228804491 |
| Principal investigator 1 | ABBVIE INC. | $43,042.02 | 12/11/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202530122 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 12/11/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240482114 |
| Principal investigator 1 | Incyte Corporation | $635.00 | 12/10/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561321 |
| Principal investigator 1 | Incyte Corporation | $99.00 | 12/10/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561388 |
| Principal investigator 1 | Incyte Corporation | $138.00 | 12/10/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561571 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $24,450.00 | 12/08/2025 | Non-covered Recipient Entity Northridge Clinical Trials Llc | A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study of Brivekimig Followed by a Maintenance Period in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226132912 |
| Principal investigator 1 | Incyte Corporation | $2,755.10 | 12/05/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561513 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $220.00 | 12/05/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289302 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $110.00 | 12/05/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289304 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $110.00 | 12/05/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289306 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $310.50 | 12/05/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289310 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $62.10 | 12/05/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289312 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $62.10 | 12/05/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289324 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $110.00 | 12/05/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289326 |
| Principal investigator 1 | ABBVIE INC. | $10,301.40 | 12/04/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202527720 |
| Principal investigator 1 | ABBVIE INC. | $8,964.60 | 12/04/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202527722 |
| Principal investigator 1 | ABBVIE INC. | $3,055.90 | 12/04/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202527724 |
| Principal investigator 1 | ABBVIE INC. | $7,932.70 | 12/04/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202527924 |
| Principal investigator 1 | Incyte Corporation | $168.00 | 12/04/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240482085 |
| Principal investigator 1 | Incyte Corporation | $423.00 | 12/04/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240482090 |
| Principal investigator 1 | Incyte Corporation | $10,000.00 | 12/04/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240482095 |
| Principal investigator 1 | Incyte Corporation | $1,363.00 | 12/04/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240482103 |
| Principal investigator 1 | Incyte Corporation | $6,232.50 | 12/04/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240482107 |
| Principal investigator 1 | Incyte Corporation | $11,232.70 | 12/04/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240482122 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 12/04/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240482127 |
| Principal investigator 1 | Incyte Corporation | $68.00 | 12/04/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240482134 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 12/04/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240482141 |
| Principal investigator 1 | Incyte Corporation | $8,597.10 | 12/04/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519536 |
| Principal investigator 1 | Incyte Corporation | $1,595.70 | 12/04/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519540 |
| Principal investigator 1 | Incyte Corporation | $11,113.10 | 12/04/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519543 |
| Principal investigator 1 | Incyte Corporation | $1,270.00 | 12/01/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561158 |
| Principal investigator 1 | Incyte Corporation | $297.00 | 12/01/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561162 |
| Principal investigator 1 | Incyte Corporation | $635.00 | 12/01/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561190 |
| Principal investigator 1 | Incyte Corporation | $99.00 | 12/01/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561347 |
| Principal investigator 1 | Incyte Corporation | $138.00 | 12/01/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561425 |
| Principal investigator 1 | Incyte Corporation | $276.00 | 12/01/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561459 |
| Principal investigator 1 | Incyte Corporation | $83.00 | 12/01/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561552 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $14,131.57 | 12/01/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289091 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $50.00 | 11/27/2025 | Non-covered Recipient Entity Northridge Clinical Trials Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226103545 |
| Principal investigator 1 | PFIZER INC. | $24,667.64 | 11/26/2025 | Non-covered Recipient Entity Northridge Clinical Trials | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228817823 |
| Principal investigator 1 | Incyte Corporation | $3,582.00 | 11/25/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519528 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $14,000.00 | 11/21/2025 | Non-covered Recipient Entity Northridge Clinical Trials | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 years to less than 18 years) with Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1235995271 |
| Principal investigator 1 | Incyte Corporation | $1,488.10 | 11/21/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561168 |
| Principal investigator 1 | Incyte Corporation | $2,122.00 | 11/21/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561172 |
| Principal investigator 1 | Incyte Corporation | $2,244.00 | 11/21/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561179 |
| Principal investigator 1 | Incyte Corporation | $2,244.00 | 11/21/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561184 |
| Principal investigator 1 | Incyte Corporation | $3,642.00 | 11/21/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561326 |
| Principal investigator 1 | Incyte Corporation | $52.00 | 11/21/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561336 |
| Principal investigator 1 | Incyte Corporation | $52.00 | 11/21/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561343 |
| Principal investigator 1 | Incyte Corporation | $200.00 | 11/21/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561520 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 11/20/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240482073 |
| Principal investigator 1 | Incyte Corporation | $52.00 | 11/17/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561559 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 11/14/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240482079 |
| Principal investigator 1 | Incyte Corporation | $1,244.70 | 11/14/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519532 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $4,242.61 | 11/14/2025 | Non-covered Recipient Entity Northridge Clinical Trials Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226103341 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $38,856.59 | 11/10/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S | No dispute reported | 06/30/2026 | 1190312821 |
| Principal investigator 1 | ABBVIE INC. | $628.80 | 11/05/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202522485 |
| Principal investigator 1 | ABBVIE INC. | $2,178.80 | 11/05/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202522487 |
| Principal investigator 1 | ABBVIE INC. | $12,631.90 | 11/05/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202522489 |
| Principal investigator 1 | ABBVIE INC. | $2,125.10 | 11/04/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202520643 |
| Principal investigator 1 | ABBVIE INC. | $1,745.50 | 11/04/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202520765 |
| Principal investigator 1 | ABBVIE INC. | $5,493.90 | 11/04/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202520767 |
| Principal investigator 1 | PFIZER INC. | $20,529.52 | 11/04/2025 | Non-covered Recipient Entity Northridge Clinical Trials | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228817829 |
| Principal investigator 1 | Incyte Corporation | $52.00 | 11/03/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561372 |
| Principal investigator 1 | Incyte Corporation | $99.00 | 11/03/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561507 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $10,390.47 | 10/31/2025 | Non-covered Recipient Entity Northridge Clinical Trials Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226103550 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 10/30/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202519875 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 10/29/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240482038 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 10/29/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240482054 |
| Principal investigator 1 | Incyte Corporation | $4,785.30 | 10/29/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519524 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $912.53 | 10/29/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223287783 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $6,660.00 | 10/27/2025 | Non-covered Recipient Entity Elite Clinical Network/ Northridge Clinical Trials | Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis | No dispute reported | 06/30/2026 | 1244051370 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,226.11 | 10/24/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223287641 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,098.05 | 10/23/2025 | Non-covered Recipient Entity Northridge Clinical Trials Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226103540 |
| Principal investigator 1 | Incyte Corporation | $200.00 | 10/22/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561126 |
| Principal investigator 1 | Incyte Corporation | $200.00 | 10/22/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561132 |
| Principal investigator 1 | Incyte Corporation | $200.00 | 10/22/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561140 |
| Principal investigator 1 | Incyte Corporation | $3,642.00 | 10/22/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561202 |
| Principal investigator 1 | Incyte Corporation | $3,642.00 | 10/22/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561208 |
| Principal investigator 1 | Incyte Corporation | $3,642.00 | 10/22/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561215 |
| Principal investigator 1 | Incyte Corporation | $52.00 | 10/22/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561283 |
| Principal investigator 1 | Incyte Corporation | $52.00 | 10/22/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561291 |
| Principal investigator 1 | Incyte Corporation | $52.00 | 10/22/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561297 |
| Principal investigator 1 | Incyte Corporation | $52.00 | 10/22/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561303 |
| Principal investigator 1 | Incyte Corporation | $207.00 | 10/22/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561309 |
| Principal investigator 1 | Incyte Corporation | $97.00 | 10/22/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561363 |
| Principal investigator 1 | Incyte Corporation | $2,335.00 | 10/22/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561401 |
| Principal investigator 1 | Incyte Corporation | $2,335.00 | 10/22/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561405 |
| Principal investigator 1 | Incyte Corporation | $2,335.00 | 10/22/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561413 |
| Principal investigator 1 | Incyte Corporation | $2,335.00 | 10/22/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561420 |
| Principal investigator 1 | Incyte Corporation | $504.35 | 10/22/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561490 |
| Principal investigator 1 | Incyte Corporation | $2,122.00 | 10/22/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561494 |
| Principal investigator 1 | Incyte Corporation | $2,122.00 | 10/22/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561501 |
| Principal investigator 1 | Incyte Corporation | $2,244.00 | 10/22/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561527 |
| Principal investigator 1 | Incyte Corporation | $2,244.00 | 10/22/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561532 |
| Principal investigator 1 | Incyte Corporation | $121.00 | 10/22/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561542 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $13,877.98 | 10/22/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287315 |
| Principal investigator 1 | ABBVIE INC. | $5,305.17 | 10/16/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202517339 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $10,075.00 | 10/15/2025 | Non-covered Recipient Entity Northridge Clinical Trials Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226103347 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $50.00 | 10/15/2025 | Non-covered Recipient Entity Northridge Clinical Trials Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226103353 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $5,000.00 | 10/15/2025 | Non-covered Recipient Entity Northridge Clinical Trials Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226103358 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $100.00 | 10/15/2025 | Non-covered Recipient Entity Northridge Clinical Trials Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226103364 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $50.00 | 10/15/2025 | Non-covered Recipient Entity Northridge Clinical Trials Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226103529 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $50.00 | 10/15/2025 | Non-covered Recipient Entity Northridge Clinical Trials Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226103533 |
| Principal investigator 1 | ABBVIE INC. | $6,486.76 | 10/09/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202516227 |
| Principal investigator 1 | ABBVIE INC. | $7,632.00 | 10/09/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202516229 |
| Principal investigator 1 | ABBVIE INC. | $6,354.10 | 10/09/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202516233 |
| Principal investigator 1 | ABBVIE INC. | $5,280.70 | 10/09/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202516235 |
| Principal investigator 1 | ABBVIE INC. | $2,125.10 | 10/09/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202516393 |
| Principal investigator 1 | ABBVIE INC. | $2,033.70 | 10/09/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202516395 |
| Principal investigator 1 | Incyte Corporation | $1,449.00 | 10/09/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240482042 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 10/09/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240482061 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 10/09/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240482067 |
| Principal investigator 1 | Incyte Corporation | $3,452.40 | 10/09/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519520 |
| Principal investigator 1 | PFIZER INC. | $3,554.19 | 10/09/2025 | Non-covered Recipient Entity Northridge Clinical Trials | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228824411 |
| Principal investigator 1 | ABBVIE INC. | $23,997.82 | 10/06/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202513355 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14,282.70 | 10/06/2025 | Non-covered Recipient Entity Clinical Trials Research Institute | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. | No dispute reported | 06/30/2026 | 1220810316 |
| Principal investigator 1 | Incyte Corporation | $2,681.10 | 10/03/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240482050 |
| Principal investigator 1 | PFIZER INC. | $664.00 | 10/03/2025 | Non-covered Recipient Entity Northridge Clinical Trials | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228824426 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,991.08 | 10/03/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223286341 |
| Principal investigator 1 | Incyte Corporation | $1,270.00 | 10/02/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561113 |
| Principal investigator 1 | Incyte Corporation | $198.00 | 10/02/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561195 |
| Principal investigator 1 | Incyte Corporation | $276.00 | 10/02/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561379 |
| Principal investigator 1 | Incyte Corporation | $83.00 | 10/02/2025 | Non-covered Recipient Entity NORTHRIDGE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240561577 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $14,019.10 | 10/01/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286107 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $900.00 | 09/30/2025 | Non-covered Recipient Entity Elite Clinical Network/ Northridge Clinical Trials | Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis | No dispute reported | 06/30/2026 | 1244051368 |
| Principal investigator 1 | Incyte Corporation | $200.00 | 09/25/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240481985 |
| Principal investigator 1 | Incyte Corporation | $1,831.45 | 09/25/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240481991 |
| Principal investigator 1 | Incyte Corporation | $3,642.00 | 09/25/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240481997 |
| Principal investigator 1 | Incyte Corporation | $52.00 | 09/25/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240482022 |
| Principal investigator 1 | Incyte Corporation | $200.00 | 09/25/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240482027 |
| Principal investigator 1 | Incyte Corporation | $3,642.00 | 09/25/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240482032 |
| Principal investigator 1 | PFIZER INC. | $17,808.68 | 09/24/2025 | Non-covered Recipient Entity Northridge Clinical Trials | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228836854 |
| Principal investigator 1 | Incyte Corporation | $1,555.20 | 09/23/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240481974 |
| Principal investigator 1 | Incyte Corporation | $1,244.70 | 09/23/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519516 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,400.00 | 09/18/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192151207 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,000.00 | 09/18/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192151750 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,200.00 | 09/18/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192151762 |
| Principal investigator 1 | Incyte Corporation | $80.00 | 09/18/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240481952 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 09/18/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240481963 |
| Principal investigator 1 | ABBVIE INC. | $17,202.51 | 09/16/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202511024 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,329.15 | 09/15/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192097838 |
| Principal investigator 1 | Incyte Corporation | $1,567.80 | 09/12/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240481979 |
| Principal investigator 1 | Incyte Corporation | $7,231.50 | 09/12/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519511 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,656.00 | 09/12/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285349 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $724.50 | 09/12/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285351 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,700.00 | 09/08/2025 | Non-covered Recipient Entity Elite Clinical Network/ Northridge Clinical Trials | Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis | No dispute reported | 06/30/2026 | 1244051366 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 09/05/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240482002 |
| Principal investigator 1 | Incyte Corporation | $10,000.00 | 09/05/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240482010 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 09/05/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240482016 |
| Principal investigator 1 | ABBVIE INC. | $2,695.40 | 09/04/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202509052 |
| Principal investigator 1 | ABBVIE INC. | $1,425.70 | 09/04/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202509212 |
| Principal investigator 1 | Incyte Corporation | $1,449.00 | 09/04/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240481958 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 09/04/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240481968 |
| Principal investigator 1 | ABBVIE INC. | $4,671.00 | 09/03/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202507575 |
| Principal investigator 1 | ABBVIE INC. | $7,953.50 | 09/03/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202507577 |
| Principal investigator 1 | ABBVIE INC. | $7,465.20 | 09/03/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202507579 |
| Principal investigator 1 | ABBVIE INC. | $9,464.60 | 09/03/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202507581 |
| Principal investigator 1 | PFIZER INC. | $2,819.20 | 09/03/2025 | Non-covered Recipient Entity Northridge Clinical Trials | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228836736 |
| Principal investigator 1 | PFIZER INC. | $8,685.72 | 09/03/2025 | Non-covered Recipient Entity Northridge Clinical Trials | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228836910 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $25,377.54 | 09/03/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223284893 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $200.00 | 09/03/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223284987 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $60.75 | 08/27/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192151615 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 08/27/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192151627 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 08/26/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192151203 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,440.96 | 08/21/2025 | Non-covered Recipient Entity Clinical Trials Research Institute | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. | No dispute reported | 06/30/2026 | 1220810312 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,370.08 | 08/21/2025 | Non-covered Recipient Entity Clinical Trials Research Institute | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. | No dispute reported | 06/30/2026 | 1220810314 |
| Principal investigator 1 | Incyte Corporation | $2,310.30 | 08/21/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240481941 |
| Principal investigator 1 | Incyte Corporation | $3,060.00 | 08/21/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519498 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 08/19/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192097826 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 08/19/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192150706 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 08/19/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192151195 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 08/19/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192151767 |
| Principal investigator 1 | Incyte Corporation | $3,319.20 | 08/14/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240481927 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 08/14/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240481934 |
| Principal investigator 1 | Incyte Corporation | $2,709.00 | 08/14/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519507 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,771.86 | 08/13/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223284227 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 08/07/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240481946 |
| Principal investigator 1 | Incyte Corporation | $6,030.00 | 08/07/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519503 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $32,310.00 | 08/07/2025 | Non-covered Recipient Entity Elite Clinical Network/ Northridge Clinical Trials | Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis | No dispute reported | 06/30/2026 | 1244051364 |
| Principal investigator 1 | ABBVIE INC. | $2,683.70 | 08/06/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202503143 |
| Principal investigator 1 | ABBVIE INC. | $5,389.10 | 08/06/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202503145 |
| Principal investigator 1 | ABBVIE INC. | $1,885.90 | 08/05/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202501812 |
| Principal investigator 1 | ABBVIE INC. | $7,997.70 | 08/05/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202501904 |
| Principal investigator 1 | ABBVIE INC. | $1,557.00 | 08/05/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202501906 |
| Principal investigator 1 | ABBVIE INC. | $6,392.20 | 08/05/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202501908 |
| Principal investigator 1 | Eli Lilly and Company | $14,000.00 | 08/05/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE | No dispute reported | 06/30/2026 | 1187886908 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 08/05/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192097866 |
| Principal investigator 1 | PFIZER INC. | $19,443.96 | 08/05/2025 | Non-covered Recipient Entity Northridge Clinical Trials | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228840928 |
| Principal investigator 1 | Amgen Inc. | $5,700.00 | 08/01/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH | A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis | No dispute reported | 06/30/2026 | 1246640393 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,000.00 | 08/01/2025 | Non-covered Recipient Entity Clinical Trials Research Institute | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. | No dispute reported | 06/30/2026 | 1220810310 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $20,720.04 | 08/01/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283375 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $23,864.73 | 08/01/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283377 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $103.50 | 08/01/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223283487 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $100.00 | 08/01/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223283489 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $100.00 | 08/01/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223283495 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $103.50 | 08/01/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223283501 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $200.00 | 08/01/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223283503 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $750.00 | 07/31/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192151632 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 07/31/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240481916 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 07/31/2025 | Covered Recipient Teaching Hospital Northridge Medical Center - Roscoe | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240481923 |
| Principal investigator 1 | Incyte Corporation | $200.00 | 07/31/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519447 |
| Principal investigator 1 | Incyte Corporation | $6,620.40 | 07/31/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561078 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 07/24/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192150689 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,545.60 | 07/23/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223282988 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 07/22/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561095 |
| Principal investigator 1 | Incyte Corporation | $144.00 | 07/22/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561107 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 07/18/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184217489 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $108.00 | 07/17/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192150680 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $100.00 | 07/17/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192150698 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 07/17/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192151775 |
| Principal investigator 1 | Incyte Corporation | $2,797.20 | 07/17/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519444 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 07/17/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561083 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,718.82 | 07/16/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223282738 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,542.06 | 07/14/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192189478 |
| Principal investigator 1 | PFIZER INC. | $2,835.90 | 07/11/2025 | Non-covered Recipient Entity Northridge Clinical Trials | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228841773 |
| Principal investigator 1 | Incyte Corporation | $540.00 | 07/10/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519450 |
| Principal investigator 1 | Incyte Corporation | $372.00 | 07/10/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519454 |
| Principal investigator 1 | Incyte Corporation | $2,711.70 | 07/10/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519463 |
| Principal investigator 1 | Incyte Corporation | $152.00 | 07/10/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519467 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 07/10/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519471 |
| Principal investigator 1 | Incyte Corporation | $772.00 | 07/10/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519479 |
| Principal investigator 1 | Incyte Corporation | $579.00 | 07/10/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519483 |
| Principal investigator 1 | Incyte Corporation | $5,898.60 | 07/10/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519490 |
| Principal investigator 1 | Incyte Corporation | $3,110.40 | 07/10/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561100 |
| Principal investigator 1 | Incyte Corporation | $247.00 | 07/04/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519459 |
| Principal investigator 1 | Incyte Corporation | $62.00 | 07/04/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519475 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 07/04/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519485 |
| Principal investigator 1 | Incyte Corporation | $90.00 | 07/04/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519494 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 07/04/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561090 |
| Principal investigator 1 | ABBVIE INC. | $8,762.60 | 07/02/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202494761 |
| Principal investigator 1 | ABBVIE INC. | $3,114.00 | 07/02/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202494763 |
| Principal investigator 1 | ABBVIE INC. | $5,989.20 | 07/02/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202494765 |
| Principal investigator 1 | ABBVIE INC. | $2,757.40 | 07/02/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202494767 |
| Principal investigator 1 | ABBVIE INC. | $6,650.90 | 07/02/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202494769 |
| Principal investigator 1 | PFIZER INC. | $1,015.80 | 06/26/2025 | Non-covered Recipient Entity Northridge Clinical Trials | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228850302 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $941.85 | 06/25/2025 | Non-covered Recipient Entity Clinical Trials Research Institute | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431156 |
| Principal investigator 1 | Incyte Corporation | $1,244.70 | 06/24/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519424 |
| Principal investigator 1 | Incyte Corporation | $1,673.10 | 06/24/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561066 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,648.10 | 06/23/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192151185 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $20,250.00 | 06/23/2025 | Non-covered Recipient Entity Elite Clinical Network/ Northridge Clinical Trials | Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis | No dispute reported | 06/30/2026 | 1244051362 |
| Principal investigator 1 | Incyte Corporation | $2,840.40 | 06/19/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519400 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 06/19/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519407 |
| Principal investigator 1 | Incyte Corporation | $200.00 | 06/19/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519412 |
| Principal investigator 1 | Incyte Corporation | $351.00 | 06/19/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519415 |
| Principal investigator 1 | Incyte Corporation | $62.00 | 06/19/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519429 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 06/19/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561047 |
| Principal investigator 1 | Incyte Corporation | $41.00 | 06/19/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561059 |
| Principal investigator 1 | Incyte Corporation | $240.00 | 06/19/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561073 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 06/18/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) | No dispute reported | 06/30/2026 | 1202492329 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 06/18/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184209001 |
| Principal investigator 1 | Incyte Corporation | $200.00 | 06/12/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561052 |
| Principal investigator 1 | Eli Lilly and Company | $7,215.00 | 06/11/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187886066 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $150.00 | 06/06/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192150709 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $58,060.12 | 06/06/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223280942 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 06/05/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519403 |
| Principal investigator 1 | Incyte Corporation | $900.00 | 06/05/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519419 |
| Principal investigator 1 | Incyte Corporation | $1,464.30 | 06/05/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519433 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 06/05/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519439 |
| Principal investigator 1 | Incyte Corporation | $1,449.00 | 06/05/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561042 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $200.00 | 06/05/2025 | Non-covered Recipient Entity Clinical Trials Research Institute | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension | No dispute reported | 06/30/2026 | 1253118508 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $100.00 | 06/04/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223280628 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $100.00 | 06/04/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223280630 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $207.00 | 06/04/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223280644 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $207.00 | 06/04/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223280646 |
| Principal investigator 1 | ABBVIE INC. | $3,787.80 | 06/03/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202489621 |
| Principal investigator 1 | ABBVIE INC. | $6,361.00 | 06/03/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202489837 |
| Principal investigator 1 | ABBVIE INC. | $7,953.10 | 06/03/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202489839 |
| Principal investigator 1 | ABBVIE INC. | $2,893.00 | 06/03/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202489841 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $243.00 | 06/03/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192097832 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $108.00 | 06/03/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192097854 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $400.00 | 06/03/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192097860 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $121.50 | 06/03/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192150685 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $400.00 | 06/03/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192151623 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $81.00 | 06/03/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192151754 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $100.00 | 06/03/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192151758 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $243.00 | 06/03/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192159895 |
| Principal investigator 1 | Incyte Corporation | $4,392.90 | 05/28/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519370 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $161.46 | 05/28/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223280410 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $117.30 | 05/28/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223280412 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $103.50 | 05/28/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223280414 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $100.00 | 05/28/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223280416 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $100.00 | 05/26/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192151619 |
| Principal investigator 1 | Incyte Corporation | $1,244.70 | 05/22/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519385 |
| Principal investigator 1 | Incyte Corporation | $200.00 | 05/22/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519388 |
| Principal investigator 1 | Incyte Corporation | $57.00 | 05/22/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519392 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 05/22/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561001 |
| Principal investigator 1 | Incyte Corporation | $1,035.52 | 05/22/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561019 |
| Principal investigator 1 | Incyte Corporation | $616.00 | 05/22/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561024 |
| Principal investigator 1 | Incyte Corporation | $760.08 | 05/22/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561031 |
| Principal investigator 1 | Incyte Corporation | $3,123.00 | 05/22/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561037 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $18,710.00 | 05/19/2025 | Non-covered Recipient Entity Elite Clinical Network/ Northridge Clinical Trials | Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis | No dispute reported | 06/30/2026 | 1244051360 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $13,859.52 | 05/16/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192151181 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $15,477.40 | 05/16/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223279930 |
| Principal investigator 1 | Incyte Corporation | $392.40 | 05/15/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519378 |
| Principal investigator 1 | Incyte Corporation | $152.00 | 05/15/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519396 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $81.42 | 05/14/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223279730 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,800.00 | 05/14/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223279732 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $103.50 | 05/14/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223279742 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,200.00 | 05/14/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223279744 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,210.00 | 05/14/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223279746 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,300.00 | 05/14/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223279748 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $11,000.00 | 05/09/2025 | Non-covered Recipient Entity Clinical Trials Research Institute | Long term extension | No dispute reported | 06/30/2026 | 1220810302 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $58.14 | 05/09/2025 | Non-covered Recipient Entity Clinical Trials Research Institute | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431162 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $100.00 | 05/09/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223279340 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $20,842.18 | 05/09/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223279368 |
| Principal investigator 1 | Incyte Corporation | $3,189.60 | 05/08/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519382 |
| Principal investigator 1 | Incyte Corporation | $1,567.80 | 05/08/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561007 |
| Principal investigator 1 | ABBVIE INC. | $7,039.20 | 05/07/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202482727 |
| Principal investigator 1 | ABBVIE INC. | $12,500.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202482729 |
| Principal investigator 1 | ABBVIE INC. | $1,354.60 | 05/07/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202483059 |
| Principal investigator 1 | ABBVIE INC. | $1,640.20 | 05/07/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202483907 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,498.50 | 05/07/2025 | Non-covered Recipient Entity Clinical Trials Research Institute | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. | No dispute reported | 06/30/2026 | 1220810308 |
| Principal investigator 1 | ABBVIE INC. | $4,671.00 | 05/06/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202481659 |
| Principal investigator 1 | ABBVIE INC. | $4,463.00 | 05/06/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202481661 |
| Principal investigator 1 | ABBVIE INC. | $2,034.10 | 05/06/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202481663 |
| Principal investigator 1 | PFIZER INC. | $5,671.80 | 05/06/2025 | Non-covered Recipient Entity Northridge Clinical Trials | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228855514 |
| Principal investigator 1 | Incyte Corporation | $300.00 | 05/02/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519374 |
| Principal investigator 1 | Incyte Corporation | $80.00 | 05/02/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561013 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $9,868.84 | 04/28/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192189483 |
| Principal investigator 1 | Incyte Corporation | $3,956.40 | 04/28/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519350 |
| Principal investigator 1 | Incyte Corporation | $41.00 | 04/28/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240560969 |
| Principal investigator 1 | Incyte Corporation | $280.00 | 04/28/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240560988 |
| Principal investigator 1 | Incyte Corporation | $400.00 | 04/28/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240560995 |
| Principal investigator 1 | ABBVIE INC. | $7,900.82 | 04/24/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202479266 |
| Principal investigator 1 | Incyte Corporation | $1,464.30 | 04/23/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519353 |
| Principal investigator 1 | Incyte Corporation | $8,208.00 | 04/23/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240560993 |
| Principal investigator 1 | Incyte Corporation | $15,465.00 | 04/15/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519365 |
| Principal investigator 1 | Incyte Corporation | $4,473.00 | 04/15/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240560975 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $36,403.08 | 04/11/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223278038 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,498.50 | 04/09/2025 | Non-covered Recipient Entity Clinical Trials Research Institute | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. | No dispute reported | 06/30/2026 | 1220810306 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $40.50 | 04/09/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192097843 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 04/09/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192151199 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,000.00 | 04/09/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192151780 |
| Principal investigator 1 | Incyte Corporation | $15.00 | 04/08/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519357 |
| Principal investigator 1 | Incyte Corporation | $392.40 | 04/08/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519361 |
| Principal investigator 1 | Incyte Corporation | $2,917.80 | 04/08/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240560981 |
| Principal investigator 1 | PFIZER INC. | $2,299.08 | 04/08/2025 | Non-covered Recipient Entity Northridge Clinical Trials | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228857045 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $322.92 | 04/04/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223277584 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $400.00 | 04/04/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223277586 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,347.00 | 04/04/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223277588 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $300.00 | 04/04/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223277618 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $200.00 | 04/04/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223277620 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $78.00 | 04/04/2025 | Non-covered Recipient Entity Clinical Trials Research Institute | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension | No dispute reported | 06/30/2026 | 1253118486 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $84.50 | 04/04/2025 | Non-covered Recipient Entity Clinical Trials Research Institute | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension | No dispute reported | 06/30/2026 | 1253118492 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $84.50 | 04/04/2025 | Non-covered Recipient Entity Clinical Trials Research Institute | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension | No dispute reported | 06/30/2026 | 1253118497 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $84.50 | 04/04/2025 | Non-covered Recipient Entity Clinical Trials Research Institute | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension | No dispute reported | 06/30/2026 | 1253118501 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $84.50 | 04/04/2025 | Non-covered Recipient Entity Clinical Trials Research Institute | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension | No dispute reported | 06/30/2026 | 1253118505 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $2,121.60 | 04/04/2025 | Non-covered Recipient Entity Clinical Trials Research Institute | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension | No dispute reported | 06/30/2026 | 1253118517 |
| Principal investigator 1 | ABBVIE INC. | $1,640.20 | 04/03/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202472456 |
| Principal investigator 1 | ABBVIE INC. | $1,557.00 | 04/03/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202472578 |
| Principal investigator 1 | ABBVIE INC. | $1,410.10 | 04/03/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202472582 |
| Principal investigator 1 | ABBVIE INC. | $1,615.90 | 04/03/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202472961 |
| Principal investigator 1 | ABBVIE INC. | $6,432.50 | 04/03/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202472965 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $941.85 | 04/02/2025 | Non-covered Recipient Entity Clinical Trials Research Institute | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431158 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $300.00 | 04/02/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223277484 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $900.00 | 04/02/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223277500 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500.00 | 04/02/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223277502 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $400.00 | 04/01/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223277308 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $400.00 | 04/01/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223277310 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,000.00 | 03/27/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA | No dispute reported | 06/30/2026 | 1192150694 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,500.00 | 03/27/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA | No dispute reported | 06/30/2026 | 1192151190 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,100.00 | 03/26/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223277051 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $600.00 | 03/26/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223277053 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 03/25/2025 | Non-covered Recipient Entity California Dermatology Institute-Thousand Oaks | Speso moderate to severe HS Phase IIb/III | No dispute reported | 06/30/2026 | 1220771229 |
| Principal investigator 1 | Incyte Corporation | $3,582.00 | 03/25/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240560947 |
| Principal investigator 1 | PFIZER INC. | $2,485.38 | 03/22/2025 | Non-covered Recipient Entity Northridge Clinical Trials | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228858706 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $350.00 | 03/21/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192097848 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $108.00 | 03/21/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192150702 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $15,898.29 | 03/21/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192150713 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $250.00 | 03/21/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192151211 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $162.00 | 03/21/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192151637 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $81.00 | 03/21/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192151770 |
| Principal investigator 1 | UCB SA | $19,653.35 | 03/21/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB COMPARED TO USTEKINUMAB IN CHILDREN AND ADOLESCENTS FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH MODERATE TO SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 1246659122 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $15,100.00 | 03/20/2025 | Non-covered Recipient Entity Elite Clinical Network/ Northridge Clinical Trials | Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis | No dispute reported | 06/30/2026 | 1244051358 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,595.00 | 03/18/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184174266 |
| Principal investigator 1 | Incyte Corporation | $93.84 | 03/14/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240560912 |
| Principal investigator 1 | Incyte Corporation | $198.00 | 03/14/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240560916 |
| Principal investigator 1 | Incyte Corporation | $117.30 | 03/14/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240560922 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 03/14/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240560931 |
| Principal investigator 1 | Incyte Corporation | $91.08 | 03/14/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240560953 |
| Principal investigator 1 | Incyte Corporation | $123.00 | 03/14/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240560958 |
| Principal investigator 1 | Incyte Corporation | $545.08 | 03/14/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240560964 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $107.50 | 03/14/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184173892 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $380.00 | 03/14/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184173894 |
| Principal investigator 1 | ABBVIE INC. | $6,005.80 | 03/12/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202462676 |
| Principal investigator 1 | Incyte Corporation | $3,511.80 | 03/11/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240560937 |
| Principal investigator 1 | ABBVIE INC. | $3,065.90 | 03/07/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202460313 |
| Principal investigator 1 | ABBVIE INC. | $1,254.10 | 03/07/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202460317 |
| Principal investigator 1 | ABBVIE INC. | $5,954.10 | 03/07/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202460445 |
| Principal investigator 1 | ABBVIE INC. | $3,189.80 | 03/07/2025 | Non-covered Recipient Entity CALIFORNIA DERMATOLOGY INSTITUTE | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202461719 |
| Principal investigator 1 | ABBVIE INC. | $9,148.70 | 03/07/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202461823 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,187.84 | 03/07/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223276131 |
| Principal investigator 1 | ABBVIE INC. | $12,304.30 | 03/06/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202458405 |
| Principal investigator 1 | ABBVIE INC. | $6,233.20 | 03/04/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202455598 |
| Principal investigator 1 | UCB SA | $40,746.60 | 02/27/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) | No dispute reported | 06/30/2026 | 1246658338 |
| Principal investigator 1 | PFIZER INC. | $9,023.82 | 02/26/2025 | Non-covered Recipient Entity Northridge Clinical Trials | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228836863 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $77,540.55 | 02/26/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223275651 |
| Principal investigator 1 | ABBVIE INC. | $19,737.04 | 02/25/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202453803 |
| Principal investigator 1 | Incyte Corporation | $6,726.60 | 02/25/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561599 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 02/20/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184155066 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $1,909.44 | 02/20/2025 | Non-covered Recipient Entity Clinical Trials Research Institute | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension | No dispute reported | 06/30/2026 | 1253118513 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $37,805.52 | 02/19/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223275387 |
| Principal investigator 1 | ABBVIE INC. | $9,984.20 | 02/11/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202450508 |
| Principal investigator 1 | Incyte Corporation | $392.40 | 02/11/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519575 |
| Principal investigator 1 | Incyte Corporation | $41.00 | 02/11/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561605 |
| Principal investigator 1 | Incyte Corporation | $3,346.20 | 02/11/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561612 |
| Principal investigator 1 | Incyte Corporation | $320.00 | 02/11/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561620 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $9,841.52 | 02/10/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192151611 |
| Principal investigator 1 | ABBVIE INC. | $9,775.70 | 02/06/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202448113 |
| Principal investigator 1 | ABBVIE INC. | $7,561.80 | 02/06/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202448117 |
| Principal investigator 1 | ABBVIE INC. | $1,429.60 | 02/06/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202448156 |
| Principal investigator 1 | ABBVIE INC. | $6,462.00 | 02/06/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202448159 |
| Principal investigator 1 | ABBVIE INC. | $8,856.60 | 02/05/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202444823 |
| Principal investigator 1 | Incyte Corporation | $4,173.30 | 02/05/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519571 |
| Principal investigator 1 | PFIZER INC. | $8,179.53 | 02/05/2025 | Non-covered Recipient Entity Northridge Clinical Trials | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228836857 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $755.00 | 02/05/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223274865 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,000.00 | 02/03/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223274689 |
| Principal investigator 1 | UCB SA | $14,913.00 | 01/31/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa | No dispute reported | 06/30/2026 | 1246657000 |
| Principal investigator 1 | Amgen Inc. | $2,431.00 | 01/30/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) | No dispute reported | 06/30/2026 | 1246645461 |
| Principal investigator 1 | Incyte Corporation | $1,595.70 | 01/29/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519559 |
| Principal investigator 1 | Incyte Corporation | $8,000.00 | 01/29/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561583 |
| Principal investigator 1 | Incyte Corporation | $4,665.60 | 01/29/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561587 |
| Principal investigator 1 | Eli Lilly and Company | $83,439.00 | 01/28/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187887328 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 01/27/2025 | Non-covered Recipient Entity California Dermatology Institute-Thousand Oaks | Speso moderate to severe HS Phase IIb/III | No dispute reported | 06/30/2026 | 1220771227 |
| Principal investigator 1 | Eli Lilly and Company | $3,277.86 | 01/27/2025 | Non-covered Recipient Entity MEHRDAD KEVIN ARIANI MD | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187886924 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5,817.24 | 01/27/2025 | Non-covered Recipient Entity Clinical Trials Research Institute | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431160 |
| Principal investigator 1 | Avita Medical Americas, LLC | $11,935.00 | 01/23/2025 | Non-covered Recipient Entity Clinical Trials Research Institute | CTP010 Additional Vitiligo Study | No dispute reported | 06/30/2026 | 1171903449 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $310.50 | 01/22/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223274373 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $400.00 | 01/22/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223274375 |
| Principal investigator 1 | Incyte Corporation | $2,970.00 | 01/21/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519563 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 01/20/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184148956 |
| Principal investigator 1 | Incyte Corporation | $3,362.40 | 01/17/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519567 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $13,338.28 | 01/09/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL | No dispute reported | 06/30/2026 | 1192159899 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,046.80 | 01/07/2025 | Non-covered Recipient Entity Clinical Trials Research Institute | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. | No dispute reported | 06/30/2026 | 1220810304 |
| Principal investigator 1 | Incyte Corporation | $392.40 | 01/07/2025 | Non-covered Recipient Entity CLINICAL TRIALS RESEARCH INSTITUTE | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240519555 |
| Principal investigator 1 | Incyte Corporation | $1,908.90 | 01/07/2025 | Non-covered Recipient Entity NORTHRIDGE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240561594 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $13,389.15 | 01/03/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223273549 |
| Principal investigator 1 | Amgen Inc. | $92,480.45 | 01/02/2025 | Non-covered Recipient Entity CALIFORNIA DERMATOLOGY INSTITUTE | A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis | No dispute reported | 06/30/2026 | 1246639849 |
| Principal investigator 1 | Amgen Inc. | $86,611.36 | 01/02/2025 | Non-covered Recipient Entity NORTHRIDGE CLINICAL TRIALS | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246645470 |